TABLE 2.
Association of SABA a with exacerbations during the first follow‐up year among pediatric patients with asthma
| Baseline SABA canisters | 0–5 years (n = 114,378) | 6–11 years (n = 58,228) | 12–17 years (n = 46,955) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of patients | Number of events | IRR (95% CI) | Number of patients | Number of events | IRR (95% CI) | Number of patients | Number of events | IRR (95% CI) | |
| Overall | |||||||||
| 0–2 | 62,427 | 3750 | 1.00 (ref) | 39,787 | 3254 | 1.00 (ref) | 34,491 | 3852 | 1.00 (ref) |
| 3–5 | 36,694 | 3759 | 1.24 (1.18–1.31) | 14,007 | 1790 | 1.16 (1.08–1.23) | 9417 | 1657 | 1.16 (1.08–1.24) |
| 6–10 | 13,471 | 2172 | 1.57 (1.47–1.67) | 3911 | 742 | 1.31 (1.19–1.43) | 2590 | 707 | 1.44 (1.30–1.60) |
| ≥11 | 1786 | 504 | 1.86 (1.64–2.12) | 523 | 210 | 1.89 (1.57–2.26) | 457 | 264 | 1.98 (1.65–2.38) |
| 0–2 | 62,427 | 3750 | 1.00 (ref) | 39,787 | 3254 | 1.00 (ref) | 34,491 | 3852 | 1.00 (ref) |
| ≥3 | 51,951 | 6435 | 1.35 (1.29–1.42) | 18,441 | 2742 | 1.22 (1.15–1.29) | 12,464 | 2628 | 1.26 (1.19–1.34) |
| Continuous | 114,378 | 10,185 | 1.06 (1.05–1.07) | 58,228 | 5996 | 1.05 (1.04–1.06) | 46,955 | 6480 | 1.04 (1.03–1.06) |
| Atopic | |||||||||
| 0–2 | 12,728 | 1401 | 1.00 (ref) | 18,573 | 2414 | 1.00 (ref) | 19,707 | 2958 | 1.00 (ref) |
| 3–5 | 8526 | 1437 | 1.17 (1.07–1.27) | 7432 | 1336 | 1.09 (1.01–1.17) | 5780 | 1266 | 1.10 (1.02–1.19) |
| 6–10 | 3383 | 770 | 1.24 (1.12–1.38) | 2262 | 580 | 1.23 (1.11–1.36) | 1698 | 538 | 1.37 (1.22–1.53) |
| ≥11 | 461 | 193 | 1.72 (1.41–2.09) | 334 | 148 | 1.52 (1.25–1.85) | 307 | 193 | 1.83 (1.49–2.23) |
| 0–2 | 12,728 | 1401 | 1.00 (ref) | 18,573 | 2414 | 1.00 (ref) | 19,707 | 2958 | 1.00 (ref) |
| ≥3 | 12,370 | 2400 | 1.21 (1.12–1.31) | 10,028 | 2064 | 1.14 (1.07–1.22) | 7785 | 1997 | 1.20 (1.12–1.28) |
| Continuous | 25,098 | 3801 | 1.04 (1.02–1.05) | 28,601 | 4478 | 1.03 (1.02–1.05) | 27,492 | 4955 | 1.04 (1.03–1.05) |
| Nonatopic | |||||||||
| 0–2 | 49,699 | 2349 | 1.00 (ref) | 21,214 | 840 | 1.00 (ref) | 14,784 | 894 | 1.00 (ref) |
| 3–5 | 28,168 | 2322 | 1.29 (1.20–1.38) | 6575 | 454 | 1.24 (1.09–1.42) | 3637 | 391 | 1.33 (1.15–1.54) |
| 6–10 | 10,088 | 1402 | 1.78 (1.64–1.94) | 1649 | 162 | 1.39 (1.13–1.70) | 892 | 169 | 1.60 (1.28–2.00) |
| ≥11 | 1325 | 311 | 1.97 (1.67–2.32) | 189 | 62 | 2.88 (1.93–4.25) | 150 | 71 | 2.47 (1.65–3.67) |
| 0–2 | 49,699 | 2349 | 1.00 (ref) | 21,214 | 840 | 1.00 (ref) | 14,784 | 894 | 1.00 (ref) |
| ≥3 | 39,581 | 4035 | 1.44 (1.35–1.54) | 8413 | 678 | 1.32 (1.17–1.49) | 4679 | 631 | 1.44 (1.27–1.64) |
| Continuous | 89,280 | 6384 | 1.07 (1.06–1.08) | 29,627 | 1518 | 1.07 (1.05–1.09) | 19,463 | 1525 | 1.06 (1.04–1.08) |
Note: Negative binomial regression models were used; all analyses were adjusted for sex, treatment steps, and baseline exacerbation history (any type and categorized as 0, 1, and ≥2 exacerbations).Atopic diseases comprised vasomotor and allergic rhinitis, dermatitis and eczema, and allergies, including those of food and substances other than drugs and biological substances, as classified by respective ICD codes. Nonatopic disease was defined as the absence of atopic diseases.
Abbreviations: CI, confidence interval; ICD, International Statistical Classification of Diseases and Related Health Problems; IRR, incidence rate ratio; ref, reference; SABA, short‐acting β2‐agonist.
≥3 canisters versus 0–2 canisters.